Skip to main content
SpringerLink
Log in

Epimedium Flavonoids Ameliorate Neuropathological Changes and Increases IGF-1 Expression in C57BL/6 Mice Exposed to Cuprizone

  • Original Paper
  • Published:
Neurochemical Research Aims and scope Submit manuscript

Abstract

The cuprizone (CPZ)-induced toxic demyelinating model, characterized by the degeneration of oligodendrocytes, has been utilized to study multiple sclerosis-related lesions. The present study was designed to determine the effect of epimedium flavonoids (EF), the main component extracted from Epimedium sagittatum, on CPZ-induced neuropathological changes in the corpus callosum of C57BL/6 mice. Once we determined an EF-based protective effect on the corpus callosum, we sought to explore the underlying mechanism of this protection. To induce demyelination, 8-week-old mice were fed with 0.2 % CPZ for a maximum period of 6 weeks. EF treatment for a period of 3 weeks effectively decreased the breakdown of myelin, OL loss, and oligodendrocyte precursor cell accumulation in CPZ-fed mice. In addition, EF administration significantly increased the cortical expression level of insulin-like growth factor 1 (IGF-1). This study provides the first in vivo evidence of EF-based protection against CPZ-induced neuropathological changes. Furthermore, our study suggests that upregulated IGF-1 may play a role in this protection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Kipp M, Clarner T, Dang J, Copray S, Beyer C (2009) The cuprizone animal model: new insights into an old story. Acta Neuropathol 118:723–736

    Article  PubMed  Google Scholar 

  2. Yin LL, Lin LL, Zhang L, Li L (2012) Epimedium flavonoids ameliorate experimental autoimmune encephalomyelitis in rats by modulating neuroinflammatory and neurotrophic responses. Neuropharmacology 63:851–862

    Article  CAS  PubMed  Google Scholar 

  3. Skripuletz T, Bussmann JH, Gudi V, Koutsoudaki PN, Pul R, Moharregh-Khiabani D, Lindner M, Stangel M (2010) Cerebellar cortical demyelination in the murine cuprizone model. Brain Pathol 20:301–312

    Article  CAS  PubMed  Google Scholar 

  4. Yang HJ, Wang H, Zhang Y, Xiao L, Clough RW, Browning R, Li XM, Xu H (2009) Region-specific susceptibilities to cuprizone-induced lesions in the mouse forebrain: implications for the pathophysiology of schizophrenia. Brain Res 1270:121–130

    Article  CAS  PubMed  Google Scholar 

  5. Morell P, Barrett CV, Mason JL, Toews AD, Hostettler JD, Knapp GW, Matsushima GK (1998) Gene expression in brain during cuprizone-induced demyelination and remyelination. Mol Cell Neurosci 12:220–227

    Article  CAS  PubMed  Google Scholar 

  6. Lindner M, Fokuhl J, Linsmeier F, Trebst C, Stangel M (2009) Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neurosci Lett 453:120–125

    Article  CAS  PubMed  Google Scholar 

  7. García-Segura LM, Dueñas M, Fernandez-Galaz MC, Chowen JA, Argente J, Naftolin F, Torres-Aleman I (1996) Interaction of the signalling pathways of insulin-like growth factor-I and sex steroids in the neuroendocrine hypothalamus. Horm Res 46:160–164

    Article  PubMed  Google Scholar 

  8. D’Ercole AJ, Ye P, Calikoglu AS, Gutierrez-Ospina G (1996) The role of the insulin-like growth factors in the central nervous system. Mol Neurobiol 13:227–255

    Article  PubMed  Google Scholar 

  9. Mason JL, Ye P, Suzuki K, D’Ercole AJ, Matsushima GK (2000) Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination. J Neurosci 20:5703–5708

    CAS  PubMed  Google Scholar 

  10. Komoly S, Hudson LD, Webster HD, Bondy CA (1992) Insulin-like growth factor I gene expression is induced in astrocytes during experimental demyelination. Proc Natl Acad Sci USA 89:1894–1898

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Voss EV, Škuljec J, Gudi V, Skripuletz T, Pul R, Trebst C, Stangel M (2012) Characterisation of microglia during de- and remyelination: can they create a repair promoting environment? Neurobiol Dis 45:519–528

    Article  CAS  PubMed  Google Scholar 

  12. Torkildsen O, Brunborg LA, Myhr KM, Bø L (2008) The cuprizone model for demyelination. Acta Neurol Scand 188(Suppl):72–76

    Article  CAS  Google Scholar 

  13. Benetti F, Ventura M, Salmini B, Ceola S, Carbonera D, Mammi S, Zitolo A, D’Angelo P, Urso E, Maffia M, Salvato B, Spisni E (2010) Cuprizone neurotoxicity, copper deficiency and neurodegeneration. Neurotoxicology 31:509–517

    Article  CAS  PubMed  Google Scholar 

  14. Franco-Pons N, Torrente M, Colomina MT, Vilella E (2007) Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol Lett 169:205–213

    Article  CAS  PubMed  Google Scholar 

  15. Matsushima GK, Morell P (2001) The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11:107–116

    Article  CAS  PubMed  Google Scholar 

  16. Armstrong RC, Le TQ, Flint NC, Vana AC, Zhou YX (2006) Endogenous cell repair of chronic demyelination. J Neuropathol Exp Neurol 65:245–256

    Article  PubMed Central  PubMed  Google Scholar 

  17. Acs P, Kalman B (2012) Pathogenesis of multiple sclerosis: what can we learn from the cuprizone model. Methods Mol Biol 900:403–431

    Article  CAS  PubMed  Google Scholar 

  18. Wang H, Li C, Wang H, Mei F, Liu Z, Shen HY, Xiao L (2013) Cuprizone-induced demyelination in mice: age-related vulnerability and exploratory behavior deficit. Neurosci Bull 29:251–259

    Article  PubMed  Google Scholar 

  19. Zhang H, Zhang Y, Xu H, Wang L, Adilijiang A, Wang J, Hartle K, Zhang Z, Zhang D, Tan Q, Kong J, Huang Q, Li XM (2014) Olanzapine ameliorates neuropathological changes and increases IGF-1 expression in frontal cortex of C57BL/6 mice exposed to cuprizone. Psychiatry Res 216:438–445

    Article  CAS  PubMed  Google Scholar 

  20. Acs P, Kipp M, Norkute A, Johann S, Clarner T, Braun A, Berente Z, Komoly S, Beyer C (2009) 17β-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice. Glia 57:807–814

    Article  PubMed  Google Scholar 

  21. Mason JL, Jones JJ, Taniike M, Morell P, Suzuki K, Matsushima GK (2000) Mature oligodendrocyte apoptosis precedes IGF-1 production and oligodendrocyte progenitor accumulation and differentiation during demyelination/remyelination. J Neurosci Res 61:251–262

    Article  CAS  PubMed  Google Scholar 

  22. Tansey FA, Cammer W (1991) A pi form of glutathione-S-transferase is a myelin- and oligodendrocyte-associated enzyme in mouse brain. J Neurochem 57:95–102

    Article  CAS  PubMed  Google Scholar 

  23. Zhang Y, Zhang H, Wang L, Jiang W, Xu H, Xiao L, Bi X, Wang J, Zhu S, Zhang R, He J, Tan Q, Zhang D, Kong J, Li XM (2012) Quetiapine enhances oligodendrocyte regeneration and myelin repair after cuprizone-induced demyelination. Schizophr Res 138:8–17

    Article  PubMed  Google Scholar 

  24. Cho KH, Kim MW, Kim SU (1997) Tissue culture model of Krabbe’s disease: psychosine cytotoxicity in rat oligodendrocyte culture. Dev Neurosci 19:321–327

    Article  CAS  PubMed  Google Scholar 

  25. Kumar S, Biancotti JC, Yamaguchi M, de Vellis J (2007) Combination of growth factors enhances remyelination in a cuprizone-induced demyelination mouse model. Neurochem Res 32:783–797

    Article  CAS  PubMed  Google Scholar 

  26. Espinosa-Jeffrey A, Zhao P, Awosika W, Wu N, Macias F, Cepeda C, Levine M, de Vellis J (2006) Activation, proliferation and commitment of endogenous stem/progenitor cells to the oligodendrocyte lineage by TS1 in a rat model of dysmyelination. Dev Neurosci 28:488–498

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Nos. 81001656, 81341088), Beijing Nova Star Program in Science and Technology (No. Z12111000250000), Capital Medical Development Special Program (No. 2011-1001-06), and the Beijing Organization Department of the Municipal Party Committee Project for Highly Talented Men (2012D005018000010).

Conflict of interest

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

  1. Clinical College of Integrative Medicine, Anhui University of Chinese Medicine, 103 Meishan Road, Hefei, 230038, Anhui Province, People’s Republic of China

    Mengru Liang & Guangliang Chen

  2. Department of Pharmacology, Xuan Wu Hospital of Capital Medical University, Beijing Geriatric Medical Research Center, Key Laboratory for Neurodegenerative Diseases of Ministry of Education, 45 Changchun Street, Beijing, 100053, People’s Republic of China

    Mengru Liang, Yongyan Chen, Li Zhang, Lin Li & Linlin Yin

Authors
  1. Mengru Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yongyan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guangliang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Linlin Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Guangliang Chen or Linlin Yin.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 996 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liang, M., Chen, Y., Zhang, L. et al. Epimedium Flavonoids Ameliorate Neuropathological Changes and Increases IGF-1 Expression in C57BL/6 Mice Exposed to Cuprizone. Neurochem Res 40, 492–500 (2015). https://doi.org/10.1007/s11064-014-1490-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11064-014-1490-0

Keywords

Search

Navigation